On Oct 13, 2016, The Court of Appeal (UK) has delivered its much-anticipated decision in the dispute concerning Warner-Lambert’s second medical use patent for pain indication of pregabalin and skinny labelled generic products. The Court of Appeal has upheld the decision of lower court which held European Patent (UK) No. 0 934 061 invalid in Nov 2015. Court subsequently decided that it would be an abuse of process for Warner-Lambert to amend a claim of the Patent to limit its scope and thereby exclude part of the claim vulnerable to the insufficiency attack.